Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion 1 – Immunotherapy of cancer

4157 - A novel affinity-enhanced NY-ESO-1-targeting TCR-redirected T cell transfer exhibited early-onset cytokine release syndrome and subsequent tumor responses in synovial sarcoma patients


28 Sep 2019


Poster Discussion 1 – Immunotherapy of cancer


Hiroyoshi Hattori


Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253


H. Hattori1, M. Ishihara2, S. Kitano3, Y. Miyahara4, H. Kato5, H. Mishima6, N. Yamamoto7, T. Funakoshi8, T. Kojima9, T. Sasada10, E. Sato11, S. Okamoto12, D. Tomura12, H. Chono12, I. Nukaya12, J. Mineno12, H. Ikeda13, T. Watanabe14, S. Kageyama14, H. Shiku14

Author affiliations

  • 1 Laboratory Of Advanced Therapy, National Hospital Organization, Nagoya Medical Center, 460-0001 - Nagoya/JP
  • 2 Cancer Center, Mie University Hospital, 514-8507 - Tsu/JP
  • 3 Experimental Therapeutics, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 4 Immuno-gene Therapy, Mie University, 514-8507 - Tsu/JP
  • 5 Transfusion Medicine, Aichi Medical University, 480-1195 - Nagakute/JP
  • 6 Cancer Center, Aichi Medical University, 480-1195 - Nagakute/JP
  • 7 Developmental Therapeutics, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 8 Dermatology, Keio University School of Medicine, 160-8582 - Tokyo/JP
  • 9 Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 10 Cancer Vaccine Center, Kanagawa Cancer Center Research Institute, Yokohama/JP
  • 11 Human Pathology, Tokyo Medical University, Tokyo/JP
  • 12 Bioindustry Business Unit, Takara Bio Inc., Kusatsu/JP
  • 13 Oncology, Nagasaki University, 852-8523 - Nagasaki/JP
  • 14 Department Of Immuno-gene Therapy, Mie University, 514-8507 - Tsu/JP


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4157


Adoptive transfer of TCR-redirected T cells has been reported to exhibit efficacy in some patients with melanoma and sarcoma. However, cytokine release syndrome (CRS) or its relations to tumor response has not been well documented. This study aimed to evaluate clinical responses in association with the cell kinetics and CRSs after transfer of high-affinity NY-ESO-1 TCR-gene transduced T cells in cancer patients.


We developed a novel-type affinity-enhanced NY-ESO-1-specific TCR and an originally-developed retrovirus vector that encodes siRNA to silence endogenous TCR creation. The NY-ESO-1/TCR sequence was mutated for high affinity with replacements of G50A and A51E in CDR2 region. This is a first-in-human clinical trial of the novel NY-ESO-1-specfic TCR-T cell transfer to evaluate the safety, in vivo cell kinetics and clinical responses. It was designed as a cell-dose escalation from 5 x108 to 5 x109 cells. NY-ESO-1-expressing refractory cancer patients were enrolled, with 3 + 3 cohort design. Cyclophosphamide (1,500mg/m2) were administered prior to the TCR-T cell transfer as pre-conditioning.


Nine patients were treated with the TCR-T cells that expanded in peripheral blood with a dose-dependent manner, associated with rapid proliferation within 5 days after infusion. Three patients receiving 5x109 cells developed early-onset CRSs, with elevated levels of serum IL-6, IFN-γ. The CRSs on day1 or 2 were well managed with tocilizumab treatment. Three synovial sarcoma patients exhibited tumor shrinkage and partial responses, and they all had high-expression of NY-ESO-1 in the tumor samples, namely, 75% or more. Exploratory analysis revealed that multiple chemotactic cytokines including CCL2 and CCL7, and IL-3 increased in the serum from the patients with CRS. The proportions of effector-memory phenotype T cells in the infused cell-product were significantly associated with CRS development.


The affinity-enhanced NY-ESO-1/TCR-T cell transfer exhibited early-onset CRS in association with in vivo cell proliferation and sequential tumor responses in the patients with high-NY-ESO-1-expressing synovial sarcoma.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

The authors.


Japan Agency for Medical Research and Development.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.